Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

16.09.19	Sanofi, Abbott To Integrate Glucose Sensing And Insulin Delivery Technologies (RTTNews)
16.09.19	Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed (GlobeNewswire)
15.09.19	FDA Finds Cancer-causing Impurity In Ranitidine (RTTNews)
28.08.19	Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9 (GlobeNewswire)
06.08.19	ALNY To Face FDA In Feb., PODD Ups Outlook Again, Catalysts Galore For XLRN (RTTNews)
06.08.19	Sanofi:EU Oks Dupixent For Adolescents With Moderate-to-Severe Atopic Dermatitis (RTTNews)
06.08.19	Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis (GlobeNewswire)
06.08.19	Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis (GlobeNewswire)
29.07.19	Sanofi Q2 Business Net Income Rises; Lifts 2019 Guidance - Quick Facts (RTTNews)
27.07.19	Sanofi Terminates Partnership With Lexicon To Develop Diabetes Drug (RTTNews)
26.07.19	Sanofi : Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon (GlobeNewswire)
23.07.19	Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care (GlobeNewswire)
10.07.19	Sanofi: FDA To Review Isatuximab As Potential Treatment For RRMM (RTTNews)
10.07.19	Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma (GlobeNewswire)
02.07.19	Sanofi : Availability of the Pre-quarterly Results Communication (GlobeNewswire)
01.07.19	Sanofi : EU Okays Libtayo For Advanced Cutaneous Squamous Cell Carcinoma (RTTNews)
01.07.19	Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union (GlobeNewswire)
28.06.19	Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent - Quick Facts (RTTNews)
28.06.19	Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents (GlobeNewswire)
27.06.19	Sanofi Says FDA To Review Meningococcal Vaccine Candidate MenQuadfi (RTTNews)
27.06.19	Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate (GlobeNewswire)
26.06.19	Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis (GlobeNewswire)
21.06.19	Regeneron Pharma: REGN3500 Meets Primary Endpoint In Phase 2 Study (RTTNews)
21.06.19	Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma (GlobeNewswire)
18.06.19	Sanofi Partnering Google To Develop Virtual Healthcare Lab (RTTNews)
18.06.19	Sanofi and Google to develop new healthcare Innovation Lab (GlobeNewswire)
09.06.19	Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments (GlobeNewswire)
07.06.19	Sanofi Appoints Novartis Executive Paul Hudson As CEO (RTTNews)
07.06.19	Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer (GlobeNewswire)
02.06.19	Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma (GlobeNewswire)
24.05.19	FDA Approves Dengvaxia, The Dengue Vaccine (RTTNews)
07.05.19	Regeneron & Sanofi: Dupixent Approved For Severe Asthma Indication In EU (RTTNews)
07.05.19	Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission (GlobeNewswire)
30.04.19	Sanofi: Annual General Meeting of April 30, 2019 (GlobeNewswire)
29.04.19	Sanofi: FDA Approves Praluent To Prevent Heart Attack, Stroke, Unstable Angina (RTTNews)
27.04.19	Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization (GlobeNewswire)
26.04.19	ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes (GlobeNewswire)
26.04.19	CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma (GlobeNewswire)
26.04.19	Biotech Stocks Facing FDA Decision In May 2019 (RTTNews)
26.04.19	Sanofi Q1 Profit Rises; Backs 2019 Business EPS Outlook - Quick Facts (RTTNews)
08.04.19	Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance (GlobeNewswire)
04.04.19	Denali Therapeutics - On The Move (RTTNews)
26.03.19	Biotech Stocks Facing FDA Decision In April (RTTNews)
23.03.19	Sanofi: FDA Issues CRL For Zynquista (RTTNews)
22.03.19	Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin) (GlobeNewswire)
15.03.19	Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease (GlobeNewswire)
08.03.19	Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report (GlobeNewswire)
08.03.19	Regeneron And Sanofi Say FDA Accept For Priority Review SBLA For Dupixent (RTTNews)
08.03.19	Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (GlobeNewswire)
01.03.19	Regeneron Says CHMP Recommends Approval Of Dupixent For Asthma Indication (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

21.11.24		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
21.11.24		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
21.11.24		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
21.11.24		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
21.11.24		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
21.11.24		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
21.11.24		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
21.11.24		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus

21.11.24

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

21.11.24

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

21.11.24

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

21.11.24

SDAX aktuell: SDAX zum Handelsende auf grünem Terrain

21.11.24

Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen

21.11.24

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone